Dec 21, 2021 7:30 am EST MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
Dec 09, 2021 7:30 am EST MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
Nov 30, 2021 7:30 am EST MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
Nov 16, 2021 7:30 am EST MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
Nov 15, 2021 7:30 am EST MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline